Since 2014, the overseas investment transactions made by enterprises based in mainland China in the medicine field have surged, with the transaction volume climbing by over six times, the transaction amount in the first half of 2017 reaching USD4,353 million(approx. CNY28.95 billion), and the compound annualized growth rate increasing to 85%.
In light of the "One Belt, One Road" strategy, Asia-pacific region is expected to be an emerging investment destination focused by Chinese investors. At the same time, the countries and regions in Europe and North America, domestic investors, especially private businesses, perhaps face greater pressure and challenges in overseas investment.
Moreover, with the continuous promotion of the "One Belt, One Road" strategy, an increasingly number of overseas investors may access to China to invest in the medicine field, particularly in the areas that promote development of the pension services in China.